FDA permits Swiss attempt to study benefits of CXL
In a first research of its kind, the Swiss-based Peschke Meditrade GmbH has initiated a investigation to study the benefits of corneal collagen cross-linking (CXL) in subjects with progressive keratoconus and corneal ectasia after prior refractive surgery. Presently keratoconus is treated through eyeglasses, hard contact lenses, and a newer treatment, INTACS plastic rings inserted into the mid layer of the cornea to flatten it, changing the shape and location of the cone. In 15-20% of the cases, cornea transplant surgery is necessary.
- Vision study to access macular pigment
- FAME study can continue without change
- SynergEyes receives award for ClearKone
- Ocutec Granted CE Mark Approval for its PEG Hydrogel-Based Contact Lens
